Targeting histone deacetylases in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a median survival below 6 months and a 5-year survival rate below 1%. Effective therapies for locally advanced or metastatic tumours are missing and curatively resected patients relapse in over 80% of the cases. Although histone deacet...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Schneider, Günter, Krämer, Oliver H, Fritsche, Petra, Schüler, Susanne, Schmid, Roland M, Saur, Dieter
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Blackwell Publishing Ltd 2010
Pynciau:
Reviews
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3828843/
https://ncbi.nlm.nih.gov/pubmed/19929947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2009.00974.x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg